BSTZ Stock Analysis: BlackRock Science | NYSE
Asset Management | NYSE, USA | Market Cap: 2.137m USD | 12M Return: 61.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.31M
Warnings
Tailwinds
No distinct edge detected
Seasonality 7 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
BlackRock Science and Technology Term Trust (BSTZ) is a closed-end equity fund launched and managed by BlackRock, Inc. through its subsidiary BlackRock Advisors, LLC. The fund invests in public equity markets globally, primarily targeting growth-oriented companies in the science and technology sectors across all market capitalizations. The trust was formed in June 2019 and is domiciled in the United States, listed on the NYSE and classified within the Financials sector under the GICS Asset Management & Custody Banks sub-industry.
As a closed-end fund, BSTZ issues a fixed number of shares that trade on an exchange like common stock, with its price determined by market demand rather than directly by the funds net asset value, often resulting in shares trading at a premium or discount to underlying holdings. The trusts focus on growth stocks in science and technology typically includes exposure to segments such as software, semiconductors, internet, and IT services, sectors generally characterized by higher earnings volatility and innovation-driven revenue growth.
- AI and semiconductor mega-cap holdings drive NAV appreciation
- Fed rate cuts lift long-duration tech growth valuations
- Discount to NAV widens amid tech sector volatility
| Net Income: 314.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA 2.95 > 1.0 |
| NWC/Revenue: 5.41% < 20% (prev -7.52%; Δ 12.94% < -1%) |
| CFO/TA -0.03 > 3% & CFO -47.8m > Net Income 314.4m |
| Net Debt (-12.8m) to EBITDA (314.8m): -0.04 < 3 |
| Current Ratio: 1.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (68.7m) vs 12m ago 100.2% < -2% |
| Gross Margin: 92.26% > 18% (prev 86.11%; Δ 6.15% > 0.5%) |
| Asset Turnover: 16.93% > 50% (prev 6.88%; Δ 10.05% > 0%) |
| Interest Coverage Ratio: 100.0k > 6 (EBIT TTM 314.8m / Interest Expense TTM 546.0) |
| A: 0.01 (Total Current Assets 31.9m - Total Current Liabilities 17.5m) / Total Assets 1.75b |
| B: 0.44 (Retained Earnings 774.4m / Total Assets 1.75b) |
| C: 0.20 (EBIT TTM 314.8m / Avg Total Assets 1.57b) |
| D: 47.69 (Book Value of Equity 1.72b / Total Liabilities 36.0m) |
| Altman-Z'' = 52.91 = AAA |
As of July 01, 2026, the stock is trading at USD 29.37 with a total of 652,878 shares traded. Over the past week, the price has changed by +0.10%, over one month by -1.15%, over three months by +38.00% and over the past year by +61.14%.
Current recommended Stop Loss: 27.60 (which is 6% or 1.5 ATR below the current price).
BlackRock Science has no consensus analysts rating.
P/E Trailing = 6.686
P/S = 6.7455
P/B = 1.2419
Revenue TTM = 266.0m USD
EBIT TTM = 314.8m USD
EBITDA TTM = 314.8m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 17.5m USD (from shortTermDebt, last quarter)
Debt = 17.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -12.8m USD (calculated: Debt 17.5m - CCE 30.3m)
Enterprise Value = 2.12b USD (2.14b + Debt 17.5m - CCE 30.3m)
Interest Coverage Ratio = 577k (Ebit TTM 314.8m / Interest Expense TTM 546.0)
EV/FCF = -44.49x (Enterprise Value 2.12b / FCF TTM -47.8m)
FCF Yield = -2.25% (FCF TTM -47.8m / Enterprise Value 2.12b)
FCF Margin = -17.95% (FCF TTM -47.8m / Revenue TTM 266.0m)
Net Margin = 118.2% (Net Income TTM 314.4m / Revenue TTM 266.0m)
Gross Margin = 92.26% ((Revenue TTM 266.0m - Cost of Revenue TTM 20.6m) / Revenue TTM)
Gross Margin QoQ = 92.21% (prev 92.32%)
Tobins Q-Ratio = 1.21 (Enterprise Value 2.12b / Total Assets 1.75b)
Interest Expense / Debt = 0.00% (Interest Expense 546.0 / Debt 17.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 248.7m (EBIT 314.8m * (1 - 21.00%))
Current Ratio = 1.82 (Total Current Assets 31.9m / Total Current Liabilities 17.5m)
Debt / Equity = 0.01 (Debt 17.5m / totalStockholderEquity, last quarter 1.72b)
Debt / EBITDA = -0.04 (Net Debt -12.8m / EBITDA 314.8m)
Debt / FCF = 0.27 (negative FCF - burning cash) (Net Debt -12.8m / FCF TTM -47.8m)
Total Stockholder Equity = 1.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.01% (Net Income 314.4m / Total Assets 1.75b)
RoE = 19.77% (Net Income TTM 314.4m / Total Stockholder Equity 1.59b)
RoCE = 19.80% (EBIT 314.8m / Capital Employed (Equity 1.59b + L.T.Debt 0.0))
RoIC = 14.29% (NOPAT 248.7m / Invested Capital 1.74b)
WACC = 11.16% (E(2.14b)/V(2.15b) * Re(11.25%) + D(17.5m)/V(2.15b) * Rd(0.00%) * (1-Tc(0.21)))
Discount Rate = 11.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 25.01 | Cagr: -5.51%
[DCF] Fair Price = unknown (Cash Flow -47.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0